Metrics to compare | 7827 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship7827PeersSector | |
|---|---|---|---|---|
P/E Ratio | −29.2x | −4.0x | −0.2x | |
PEG Ratio | −0.49 | −0.01 | 0.00 | |
Price / Book | 12.6x | 2.5x | 2.6x | |
Price / LTM Sales | 52.0x | 13.3x | 2.7x | |
Upside (Analyst Target) | - | 409.3% | 69.6% | |
Fair Value Upside | Unlock | 14.5% | 11.7% | Unlock |
HanchorBio Inc. engages in the research and development of new anti-cancer drugs in Hong Kong and Mainland China. The companys product pipeline consists of HCB101, which is in phase II clinical trial to treat head and neck cancer, triple-negative breast cancer, gastric cancer, colorectal cancer, and small cell lung cancer; HCB301, which is in phase I clinical trial for the treatment of hematologic malignancies, head and neck cancer, and solid tumors; and HCB303, which is in preclinical trial to treat hematologic malignancies, head and neck cancer, and solid tumors. Its technology is the Fc-Based Designer Biologics platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutic. HanchorBio Inc. was founded in 2008 and is based in Taipei, Taiwan.